Core Viewpoint - The announcement highlights that Shandong Huate Dain Health Co., Ltd.'s subsidiary, Dain Pharmaceutical, has received a drug registration certificate for a medication aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-17, which is expected to enhance the company's product pipeline and competitive position in the pediatric health sector [1][2]. Group 1: Drug Registration Certificate Details - Dain Pharmaceutical has obtained the drug registration certificate for Clonidine Hydrochloride Extended-Release Tablets, with the certificate number 2025S03966 [1]. - The medication is intended for the treatment of ADHD in children and adolescents aged 6-17, either alone or as an adjunct to central nervous system stimulants [1]. Group 2: Impact on the Company - The acquisition of the drug registration certificate is anticipated to enrich the company's product line in the ADHD treatment area, supporting the realization of its strategic development and enhancing its competitiveness [2]. - The introduction of this medication is expected to positively impact the company's commitment to children's health and its performance [2].

Core Viewpoint - The company announced that its subsidiary, Dain Pharmaceutical, has received approval from the National Medical Products Administration for the registration of Clonidine Hydrochloride Extended-Release Tablets, specifically for the treatment of ADHD in children aged 6-17 years [2] Group 1 - The approved product is Clonidine Hydrochloride Extended-Release Tablets with a specification of 0.1mg [2] - The approval number for the product is Guoyao Zhunzi H20256411, and it is valid until December 29, 2030 [2]

Group 1 - Zhongke Lanyun expects a net profit of 1.4 billion to 1.43 billion yuan for 2025, representing a year-on-year increase of 366.51% to 376.51% due to significant gains from investments in Moer Thread and Muxi shares [1] - Chuanjinnuo anticipates a net profit of 430 million to 480 million yuan for 2025, reflecting a year-on-year growth of 144.24% to 172.64% [2] - Guangqi Technology signed contracts for mass production of metamaterials totaling 264 million yuan with four clients [4] Group 2 - Daqin Railway reported a cumulative freight volume of 390 million tons for 2025, a decrease of 0.54% year-on-year [5] - Nanjing Panda clarified that it has no related business in the brain-computer interface sector and has not generated any sales revenue from it [6] - Tianhe Magnetic Materials announced that shareholder Nantong Yuanlong plans to reduce its stake by up to 3% [7] Group 3 - Yili Group's chairman plans to reduce his stake by up to 0.98% within a specified timeframe [12] - Ankai Bus reported a 46.8% year-on-year increase in bus sales for 2025, with total sales reaching 8,569 units [13] - Giant Star Agriculture reported a December 2025 pig sales volume of 666,400 heads, a year-on-year increase of 118.23% [22] Group 4 - China Nuclear Power's cumulative commercial power generation for 2025 is expected to grow by 12.98% year-on-year, reaching 244.43 billion kWh [38] - Weili Medical anticipates a net profit of 75 million to 95 million yuan for 2025, a decrease of 66% to 57% year-on-year [39] - Aonong Biological reported a December 2025 pig sales volume of 162,300 heads, a year-on-year increase of 28.39% [40]

Core Viewpoint - The company Huate Dain has received a drug registration certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years [1] Group 1 - The drug is intended for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]

Core Viewpoint - Huatai Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received a Drug Registration Certificate from the National Medical Products Administration for its product, Clonidine Hydrochloride Sustained-Release Tablets, which is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The product is specifically used as a standalone or adjunctive treatment with central nervous system stimulants for ADHD [1]

Core Viewpoint - The company announced that its subsidiary, Shandong Dain Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets, aimed at treating Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6-17 years [1] Group 1 - The drug is indicated for use either alone or as an adjunct to central nervous system stimulants in the treatment of ADHD [1]

Group 1 - The core point of the article is that Huate Dain (000915.SZ) announced that its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (referred to as Dain Pharmaceutical), has received a drug registration certificate from the National Medical Products Administration for a new medication, Clonidine Hydrochloride Sustained-Release Tablets [1] Group 2 - The drug is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years, either as a standalone treatment or as an adjunct to central nervous system stimulants [1]

证券代码：000915 证券简称：华特达因 公告编号：2026-001 山东华特达因健康股份有限公司 | 药品名称 | | | 盐酸可乐定缓释片 | | | --- | --- | --- | --- | --- | | 主要成分 | | | 盐酸可乐定 | | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 规格 | 0.1mg | | 注册分类 | 化学药品 3 类 | | 药品注册标准编号 | YBH32192025 | | 药品有效期 | 36 个月 | | 包装规格 | 1 瓶/盒 | | 处方药/非处方药 | 处方药 | | 上市许可持有人 | | | 山东达因海洋生物制药股份有限公司 | | | 生产企业 | | | 山东达因海洋生物制药股份有限公司 | | | 药品批准文号 | 国药准字 | H20256411 | 药品批准文号有效期 | 至 2030 年 12 月 29 日 | 一、药品注册证书基本情况 二、药品的其他相关情况说明 本品用于单独或辅助中枢兴奋药治疗 6-17 岁儿童和青少年的注 意缺陷多动障碍（ADHD）。 三、获得药品注册证书对公司的影响及风险提示 ...

Core Viewpoint - Core viewpoint of the article highlights that Coree Co., Ltd., a leading pediatric pharmaceutical sales service provider in China, is planning to go public on the Hong Kong Stock Exchange, with a focus on digital solutions to enhance the pharmaceutical supply chain and expand its international business [1][4]. Company Overview - Coree Co., Ltd. is the largest pediatric pharmaceutical sales service provider in China, with projected revenues of $282 million in 2024 and a net profit of $22 million. However, the company experienced a nearly 30% decline in revenue and over 50% decline in net profit in the first half of 2025 compared to the previous year [1][4]. - The company operates a comprehensive medical health solution supply chain, focusing on pharmaceutical marketing, promotion, and sales, as well as the research, production, and distribution of maternal and infant nutritional supplements [1][2]. Market Position - According to Frost & Sullivan, Coree ranks among the top ten pharmaceutical marketing and sales companies in China by revenue, holding a significant market share of 15.9% in the pediatric pharmaceutical marketing sector [1][6][9]. - The company has a vast sales network covering all 31 provinces in mainland China, with over 1,500 distributors and access to approximately 110,000 clinics, 310,000 pharmacies, and 3,600 hospitals, including 68 top-tier hospitals [2][4]. Financial Performance - The financial performance of Coree shows a decline in revenue and profit margins. For the fiscal year ending December 31, 2024, the revenue is projected to be approximately $322 million, with a gross profit of around $140 million and a net profit of $17 million. The first nine months of 2025 show a year-on-year revenue decline of 29.63% and a net profit decline of 50.15% [4][6]. - The company's revenue is heavily reliant on exclusive distribution rights for two flagship pediatric prescription drugs, which accounted for 57% to 62% of total procurement from Hanmi Pharmaceutical during the reporting periods [3][4]. Industry Overview - The pediatric pharmaceutical marketing and sales industry in China is expected to grow from RMB 6.4 billion in 2020 to RMB 9.6 billion in 2024, with a compound annual growth rate (CAGR) of 10.7%. The market is projected to reach RMB 14.8 billion by 2029, with a CAGR of 9.0% from 2024 to 2029 [6][9]. - The industry is characterized by high concentration, with the top five companies holding a combined market share of 30.2% in 2024 [9][10].

Group 1 - The company held its fifth temporary board meeting of the 11th session on December 22, 2025, with all 9 directors present, confirming compliance with legal and regulatory requirements [2] - The board approved several proposals unanimously, including amendments to the General Manager's Office Meeting Rules, the Board Secretary Work System, and the Information Disclosure Management System [3][4] - The board also approved the establishment of a temporary and exemption management system for information disclosure and agreed to extend the operational period of the Everbright Wealth Medical Fund until January 30, 2028, along with signing a supplementary agreement [4]